Workshop on a tailored clinical approach in biosimilar development, Online, European Medicines Agency, Amsterdam, the Netherlands, from 22 September 2025, 09:00 (CEST) to 22 September 2025, 16:00 (CEST)

Human medicines European public assessment report (EPAR): Viagra, sildenafil, Date of authorisation: 13/09/1998, Revision: 51, Status: Authorised

Human medicines European public assessment report (EPAR): Revatio, sildenafil, Date of authorisation: 28/10/2005, Revision: 54, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Viatris Pharma (previously Pregabalin Pfizer), pregabalin, Date of authorisation: 10/04/2014, Revision: 36, Status: Authorised

UPD registration guide for UI and API users

Worksharing of variations (veterinary medicines)

Human medicines European public assessment report (EPAR): Bomyntra, denosumab, Date of authorisation: 17/07/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Zirabev, bevacizumab, Date of authorisation: 14/02/2019, Revision: 17, Status: Authorised

First European Medicines Agency (EMA) and Association of Clinical Research Organizations (ACRO) bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 2 September 2025

Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Date of authorisation: 16/11/2011, Revision: 31, Status: Authorised